查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1858085

依治疗类型、给药途径、最终用户、药物类别和类淀粉沉积症类型分類的类淀粉沉积症治疗市场－2025-2032年全球预测

Amyloidosis Treatment Market by Treatment Type, Route Of Administration, End User, Drug Class, Amyloidosis Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，类淀粉沉积症治疗市场将成长至 102.1 亿美元，复合年增长率为 7.54%。

关键市场统计数据
基准年 2024 57亿美元
预计年份：2025年 61.3亿美元
预测年份 2032 102.1亿美元
复合年增长率 (%) 7.54%

全面介绍近年来淀粉样变性诊断的准确性、治疗方法的拓展以及不断发展的诊疗路径，这些因素共同塑造了当今类淀粉沉积症的管理。

类淀粉沉积症已从一种罕见且常被误诊的疾病发展成为一个治疗领域，其特点是诊断技术的快速改进和标靶治疗的广泛应用。近年来，生物标记检测法、影像学技术和多模式治疗方法的进步，使临床医生和研究人员能够更早发现疾病并进行更准确的表型分析。这些临床进展为更有效地实施治疗性介入和更密切地追踪患者预后创造了机会。

同时，治疗套件也在不断扩展，涵盖多种模式。药物治疗包括多种方法，从经典的烷化剂到新一代的TTR抑制剂和稳定剂。支持性治疗在控制症状和提高生活品质方面继续发挥关键作用，尤其是在缓解疾病疗法延长生存期并将重点转向长期管理的情况下。因此，医疗服务模式也不断调整，以平衡专科医生主导的医院护理、门诊专科诊所和居家照护的需求。

本导言透过强调诊断、治疗创新和护理服务之间的相互联繫，为更广泛的执行摘要奠定了基础，并强调了将临床证据与商业计划相结合的重要性，以抓住新兴机会并应对持续存在的准入挑战。

分子标靶治疗、早期检测和不断发展的护理服务模式如何重新定义类淀粉沉积症的临床和商业性重点

过去十年，由于分子标靶治疗、诊断演算法的改进以及临床实践模式的调整，类淀粉沉积症领域的研究格局发生了显着变化。 TTR 抑制剂和稳定器的出现重新定义了 ATTR 亚型淀粉样变性的治疗目标，并催生了直接调控潜在致病连锁的治疗方法。同时，AL类淀粉沉积症的单株抗体疗法革新了标准诱导治疗方案，并为对传统疗法抗药性的患者提供了更多选择。

诊断技术的进步，包括更灵敏的心臟影像和更精确的生物标记物，使临床医生能够更早识别淀粉样蛋白亚型，并更有把握地对患者进行风险分层。这种早期检测促使人们更加关注能够改变疾病进程而非仅仅缓解症状的干预措施，同时也凸显了循环系统、神经科、血液病学和专科诊所之间医疗协调的重要性。与治疗和诊断技术的进步同步，支付方和监管机构也做出了相应调整，建立了更完善的加速核准和有条件准入项目机制，儘管在许多地区，报销谈判仍然十分复杂。

最后，医疗系统和医疗服务提供者正在调整服务模式，以满足慢性病管理的需求。我们看到，在临床适宜的情况下，家庭输液和监测正在逐步整合，专科诊所中心也正在兴起，这些中心汇集了各方专长，能够促进复杂疗法的快速启动。这些系统性的转变正在从根本上重塑整个生态系统的投资重点、研发方向和商业策略。

评估2025年美国关税改革对类淀粉沉积症治疗药物供应链、筹资策略和病患取得途径的多方面影响

2025年实施的贸易政策发展和关税调整为美国医药和生技药品供应链的相关人员带来了新的复杂性。特别是，影响关键进口产品的累积关税措施，包括原料药、特种化学品和某些生技药品成品，加剧了本已采用精益库存和准时生产模式的供应链的成本压力。不断上涨的投入成本正推高製造商的成本结构，迫使他们重新评估其分销、采购和定价策略。

除了直接的成本影响外，关税还可能引发采购决策和合约条款的转变。主要企业可能会加快近岸外包或实现供应商多元化，以降低关税波动带来的风险；而製造外包则可能重新评估产能承诺和前置作业时间。同时，支付方和整合医疗服务网络可能会透过加强基于价值的合约谈判，并要求提供更清晰的临床获益和长期疗效的真实世界证据，来应对不断上涨的采购成本。对于规模较小的生技公司而言，投入成本增加和供应链延长带来的财务负担可能会延缓临床开发进程，并使商业化计画更加复杂。

临床医生和患者也可能受到间接影响。零星的供应中断和价格压力可能会限制患者获得特殊製剂，或导致医疗机构对某些药物进行优先排序。为了因应这种情况，具有韧性的公司正在投资供应链视觉化工具、多供应商协议和策略性库存缓衝，以确保在保持竞争力的同时，保障医疗服务的连续性。儘管贸易政策发生了更广泛的变化，但与监管机构的沟通以及公私对话仍然是确保基本治疗药物稳定供应的关键工具。

将治疗方式、分子类别、给药途径、护理环境和疾病亚型与商业性和临床决策联繫起来的细分市场主导洞察

对细分市场的详细分析揭示了临床需求与商业机会和营运风险的交汇点。依治疗类型划分，可分为药物治疗、干细胞移植及支持性治疗。药物治疗又可分为烷化剂、免疫调节剂、单株抗体、蛋白酶体抑制剂、TTR 沉默剂和 TTR 稳定剂；例如，Melphalan（烷化剂） 、来Lenalidomide（免疫调节剂）、Daratumumab妥尤单抗（单株抗体）、Bortezomib、Carfilzomib、Ixazomib（RTT）、米佐酶蛋白和可拉米佐素（RTTRTT）。稳定剂）。依给药途径划分，可分为静脉注射、口服和皮下注射，每种途径在物流、遵从性和治疗部位方面均有所不同。

从最终用户的角度来看，护理服务透过居家照护、医院和专科诊所提供，每个管道都会影响产品设计、病患支援需求和报销途径。在药物类别中，重迭的药理学分类和分子机制揭示了治疗替代和联合策略在临床上可能合理的领域。最后，类淀粉沉积症的类型——AA型、AL型、遗传性ATTR型和野生型ATTR型——具有显着不同的临床表现和进展，这会影响移植资格、缓解疾病疗法的选择以及支持治疗的重点。

综上所述，此细分矩阵支援有针对性的产品开发、精准的商业性策略、差异化的患者支援模式，并透过明确与监管审查员和支付方产生共鸣的终点和亚组分层，帮助进行临床试验设计。

不同区域的细微差别会影响全球类淀粉沉积症治疗全部区域的诊断、报销途径、供应链韧性和实施时间表。

区域动态持续影响医疗服务取得、投资和临床实践，因此需要采取不同的策略。在美洲，集中的研究基础和历来良好的创新资助环境支持新型疗法和诊断技术的快速应用，但公立和私立医疗体系中不同的支付方政策导致患者就医和报销时间存在差异。相较之下，欧洲、中东和非洲地区的情况则更为复杂，单一支付方体系使得医疗服务取得途径更加标准化，但部分市场面临的基础设施限制也减缓了高成本治疗方法的普及。

亚太市场因其生物製药生产的快速扩张和多样化的监管方式而极具吸引力。该地区多个国家正在建立本地生产能力和法律规范，旨在吸引临床研发活动并减少对外部供应链的依赖。各地区在诊断能力、专家资源和本地治疗指南方面存在差异，这会影响新治疗方法从核准到常规应用的速度。在资源匮乏的地区，支持性治疗和症状管理通常是首要任务；而在资源丰富的地区，则越来越重视缓解疾病和综合护理模式。

因此，策略性参与企业需要根据当地情况调整其商业化、医疗事务和供应策略，包括根据当地证据要求调整价值证明材料，在诊断素养较低的地方投资临床医生教育，以及建立製造或采购伙伴关係，以加快患者用药时间，同时减轻关税和物流负担。

大型製药公司的规模、生物技术创新、诊断伙伴关係以及生产策略之间的相互作用决定了其在类淀粉沉积症领域的竞争地位。

类淀粉沉积症领域的竞争格局由大型製药企业、专业生物技术公司、受託製造和诊断公司组成，它们共同塑造了该领域的创新和竞争格局。拥有完善商业性基础设施的成熟製药公司在扩大核准治疗方法的覆盖范围和协商复杂的医保报销协议方面发挥着关键作用，而灵活的生物技术公司则往往在下一代抑製剂、稳定剂和靶向生技药品的早期创新方面发挥着主导作用。

战略伙伴关係和许可协议已成为加速临床开发和产品上市的关键。治疗药物研发商与诊断服务提供者之间的合作日益重要，以确保准确识别患者，并支持支撑价值导向协议的伴随诊断策略。受託製造厂商和区域製造商也发挥关键作用，它们能够帮助降低关税影响，并建立本地化的供应链，从而缩短关键治疗方法的前置作业时间。

投资者和潜在合作伙伴应密切关注产品研发管线进展、监管里程碑以及能够凸显产品临床效用和实际应用价值的证据产生策略。那些在核准后积极收集证据、增加对患者支持服务的投入并积极与支付方和临床医生网络互动的公司，更有可能将临床疗效转化为在各种医疗环境中持续应用。

製造商、支付者和医疗保健提供者可采取的策略重点，以改善淀粉样变性治疗药物的可及性，确保供应稳定性，并展现其持续的临床价值。

产业领导者应采取多管齐下的策略，在不断变化的政策和供应挑战下，充分发挥临床价值并维持药物可及性。他们应优先投资于诊断基础设施和临床医生培训，以促进早期发现和适当的亚型分类，并提高疾病修正治疗的临床效用。同时，他们应制定循证医学方案，将随机数据与真实世界证据相结合，以支持与支付方进行深入的价值评估讨论，并降低在不同报销环境下纳入医保目录的风险。

透过供应商多角化、选择性近岸外包以及关键投入品的策略性库存缓衝，增强供应链韧性。与供应商和物流伙伴协商灵活的合约条款，以应对关税波动并确保医疗服务的连续性。产品开发应与目标患者群体的给药途径偏好相符，认识到口服和皮下製剂为居家照护提供了更多机会，而静脉注射方案通常需要医院和诊所的资源。

最后，要与包括诊断机构、专科诊所和患者权益组织在内的整个生态系统建立伙伴关係，以创建全面的护理路径，从而提高患者依从性、监测治疗效果并支持长期疾病管理。在可行的情况下采用基于结果的合同，并投资于能够实现远端监测和患者参与的数位化工具，将有助于强化治疗价值的实际应用案例，并使报销谈判更加可预测。

采用稳健的混合方法研究途径，结合临床专家见解、公开监管记录和系统性文献综述，以确保得出基于证据的结论。

本分析透过整合一手和二手研究，平衡了临床、商业和营运方面的动态因素。一手研究结合了对关键意见领袖（包括血液科医生、循环系统、神经科、专科诊所主任和采购负责人）的结构化访谈，以及与行业高管的对话，以阐明产品线发展和研发策略的背景。二手研究是对同行评审的临床文献、监管核准和附加檔更新、临床试验註册资讯以及上市公司披露资讯进行系统性回顾，并辅以对诊断指南更新和支付方政策公告的研究。

数据三角验证确保了临床研究结果与观察到的商业性行为和供应链实际情况相符。透过专家访谈获得的定性见解与已发表的试验结果和监管文件进行交叉检验，以减少偏差并完善解读。分析技术包括对定性输入进行主题综合分析，以及对区域和细分市场差异进行比较趋势分析。调查方法优先考虑假设的透明度，并明确排除对市场规模的推测或预测，重点关注可操作的资讯和基于证据的建议。

总结了将诊断进步、治疗方法多样化和技术创新转化为更广泛的患者影响所需的策略行动结论。

总之，类淀粉沉积症领域正进入一个诊断技术日益精进、治疗方法日益多样化的新阶段，二者相辅相成，为改善患者预后和实现策略性商业性成长创造了切实机会。临床医生如今能够获得更多种类的缓解疾病药物和支持策略，医疗系统也正在调整服务模式以适应慢性病管理路径。贸易政策的变化和供应链压力凸显了製定稳健筹资策略的必要性，而区域差异则要求制定量身定制的市场准入和循证医学方案。

对于整个生态系统中的相关人员，将临床创新与切实可行的准入机制和营运准备相结合，是未来的发展方向。透过投资诊断、建立策略伙伴关係以及收集有意义的真实世界证据，各机构可以缩小临床潜力与更广泛的患者获益之间的差距。本文提出的建议为应对类淀粉沉积症治疗领域不断变化的治疗、监管和商业环境提供了蓝图。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • RNA干扰疗法的快速应用重塑了遗传性转甲状腺素类淀粉沉积症治疗的模式。
  • 扩大基因筛检项目，以促进对类淀粉沉积症患者的早期诊断和介入。
  • 整合先进的淀粉样成像技术，以改善治疗监测和患者分层
  • 生技公司与大型製药公司结成策略联盟，加速新型类淀粉沉积症药物的研发
  • 报销方面的挑战和支付方政策的转变影响着病患获得高成本类淀粉沉积症治疗的机会。
  • 针对错误折迭蛋白聚集体的单株抗体类淀粉沉积症在系统性类淀粉沉积症治疗的应用
  • 增加真实世界证据研究，以便更好地了解类淀粉沉积症治疗的长期疗效和安全性

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依治疗类型类淀粉沉积症治疗市场

  • 药物治疗
    • 烷化剂
      • Melphalan
    • 免疫调节药物
      • Lenalidomide
    • 单株抗体
      • Daratumumab
    • 蛋白酶体抑制剂
      • Bortezomib
      • Carfilzomib
      • Ixazomib
    • TTR消音器
      • 伊诺塔岑
      • 派蒂西兰
    • TTR稳定器
      • 阿科拉米迪斯
      • 塔法米迪斯
  • 干细胞移植
  • 支持性护理

第九章 依给药途径分類的类淀粉沉积症治疗市场

  • 静脉注射
  • 口服
  • 皮下

第十章 依最终用户分類的类淀粉沉积症治疗市场

  • 居家照护
  • 医院
  • 专科诊所

第十一章 依药物类别分類的类淀粉沉积症治疗市场

  • 烷化剂
    • Melphalan
  • 免疫调节药物
    • Lenalidomide
  • 单株抗体
    • Daratumumab
  • 蛋白酶体抑制剂
    • Bortezomib
    • Carfilzomib
    • Ixazomib
  • TTR消音器
    • 伊诺塔岑
    • 派蒂西兰
  • TTR稳定器
    • 阿科拉米迪斯
    • 塔法米迪斯

第十二章 依类淀粉沉积症类型分類的类淀粉沉积症治疗市场

  • AA
  • AL
  • 遗传性ATTR
  • 野生型 ATTR

第十三章 各地区淀粉样类淀粉沉积症治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章类淀粉沉积症治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国类淀粉沉积症治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Pfizer Inc.
    • Alnylam Pharmaceuticals, Inc.
    • Johnson & Johnson（Janssen Biotech, Inc.）
    • Ionis Pharmaceuticals, Inc.
    • BridgeBio Pharma, Inc.
    • Prothena Corporation plc
Product Code: MRR-C002B1C996F0

The Amyloidosis Treatment Market is projected to grow by USD 10.21 billion at a CAGR of 7.54% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.70 billion
Estimated Year [2025] USD 6.13 billion
Forecast Year [2032] USD 10.21 billion
CAGR (%) 7.54%

Comprehensive orientation to recent diagnostic precision, therapeutic expansion, and evolving care pathways shaping amyloidosis management today

Amyloidosis has evolved from a rare, often misdiagnosed condition into a therapeutic area marked by rapid diagnostic refinement and a proliferation of targeted treatments. In recent years, clinicians and researchers have benefited from improved biomarker assays, imaging modalities, and multidisciplinary care pathways that together enable earlier detection and more precise phenotyping. These clinical advances create opportunities for therapeutic interventions to be deployed more effectively and for patient outcomes to be tracked with greater granularity.

Concurrently, the treatment toolkit has expanded across multiple modalities. Pharmacological treatments encompass a range of approaches from classic alkylating agents to next-generation TTR silencers and stabilizers, while autologous stem cell transplantation remains a curative-intent option for eligible patients. Supportive therapies continue to play a pivotal role in symptom control and quality-of-life enhancement, particularly as disease-modifying agents extend survival and shift focus toward long-term management. As a result, care delivery models are adapting to balance specialist-driven hospital care, outpatient specialty clinics, and increasing home-based services.

This introduction frames the broader executive summary by emphasizing the interplay between diagnostics, therapeutic innovation, and care delivery. It sets the stage for deeper analysis of market dynamics, regulatory pathways, and stakeholder strategies that follow, while underscoring the importance of integrating clinical evidence with commercial planning to capitalize on emerging opportunities and to address persistent access challenges.

How targeted molecular therapies, earlier detection, and evolving care delivery models are collectively redefining clinical and commercial priorities in amyloidosis

Over the past decade, the amyloidosis landscape has experienced transformative shifts driven by targeted molecular therapies, improved diagnostic algorithms, and a recalibration of clinical practice patterns. The arrival of TTR silencers and stabilizers has reframed treatment goals for ATTR subtypes, bringing therapies that directly modulate the underlying pathogenic cascade. At the same time, monoclonal antibody approaches for AL amyloidosis have changed standard induction regimens and expanded options for patients who were previously refractory to conventional regimens.

Diagnostic progress, including more sensitive cardiac imaging and refined biomarkers, has enabled clinicians to identify amyloid subtypes earlier and to stratify patients by risk with greater confidence. This earlier detection translates into heightened demand for interventions that can alter disease trajectory rather than simply palliate symptoms, and it increases the importance of care coordination across cardiology, neurology, hematology, and specialized clinics. Parallel to therapeutic and diagnostic advances, payer and regulatory environments have adapted by creating more robust pathways for accelerated approvals and conditional access programs, although reimbursement negotiations remain complex in many jurisdictions.

Finally, health systems and providers are adapting delivery models to accommodate chronic management needs. There is a visible shift toward integrating home-based infusion and monitoring where clinically appropriate, and toward specialty clinic hubs that concentrate expertise and facilitate rapid initiation of complex therapies. These systemic shifts are collectively reshaping investment priorities, R&D focus, and commercial strategies across the ecosystem.

Assessing the multifaceted effects of 2025 United States tariff changes on pharmaceutical supply chains, procurement strategies, and patient access in amyloidosis care

Trade policy developments and tariff adjustments instituted in 2025 have introduced another layer of complexity for stakeholders operating in the United States pharmaceutical and biologics supply chains. Cumulative tariff measures, particularly those affecting key import categories such as active pharmaceutical ingredients, specialty chemicals, and certain finished biologics components, have increased the cost pressure on supply chains that are already operating with lean inventories and just-in-time manufacturing approaches. These elevated input costs exert upward pressure on manufacturers' cost structures and force reassessment of distribution, procurement, and pricing strategies.

Beyond direct cost impacts, tariffs can induce shifts in sourcing decisions and contractual terms. Companies may accelerate nearshoring or diversify supplier bases to mitigate exposure to tariff volatility, while contract manufacturers reassess capacity commitments and lead times. In tandem, payers and integrated delivery networks may respond to rising acquisition costs by intensifying value-based contracting discussions, demanding clearer real-world evidence of clinical benefit and long-term outcomes. For smaller biotech firms, the financial strain of increased input costs and elongated supply chains can slow clinical development timelines and complicate commercialization plans.

Clinicians and patients can also experience indirect effects: sporadic supply disruptions or pricing pressures may constrain access to specialized formulations or result in prioritization schemes by providers. In response, resilient companies are investing in supply chain visibility tools, multi-sourcing agreements, and strategic inventory buffers to preserve continuity of care while maintaining competitive positioning. Regulatory engagement and public-private dialogue remain important levers to ensure essential therapies maintain stable availability despite broader trade policy shifts.

Segment-driven insights that link therapeutic modality, molecular class, administration route, care setting, and disease subtype to commercial and clinical decision-making

A granular view of segmentation illuminates where clinical needs intersect with commercial opportunity and operational risk. Based on treatment type, the therapeutic landscape encompasses pharmacological treatment, stem cell transplantation, and supportive therapy, with pharmacological options further categorized into alkylating agents, immunomodulators, monoclonal antibodies, proteasome inhibitors, TTR silencers, and TTR stabilizers; examples within these classes include melphalan among alkylating agents, lenalidomide among immunomodulators, daratumumab within monoclonal antibodies, bortezomib, carfilzomib and ixazomib among proteasome inhibitors, and inotersen and patisiran representing TTR silencers while acoramidis and tafamidis exemplify TTR stabilizers. Based on route of administration, therapies span intravenous, oral, and subcutaneous delivery, each of which imposes distinct logistical, adherence, and site-of-care implications for deployment.

Examining end users, care is delivered across home care settings, hospitals, and specialty clinics, and each channel shapes product design, patient support needs, and reimbursement pathways. Based on drug class segmentation, the overlap between pharmacological taxonomy and molecular mechanism highlights where therapeutic substitution or combination strategies are clinically plausible. Finally, by amyloidosis type including AA, AL, hereditary ATTR, and wild-type ATTR, clinical presentation and progression differ markedly, which in turn influence the suitability of transplantation, the selection of disease-modifying agents, and the emphasis on supportive care.

Taken together, this segmentation matrix supports targeted product development, precision commercial approaches, and differentiated patient support models. It also informs clinical trial design by clarifying endpoints and subgroup stratification that resonate with regulatory reviewers and payer assessments.

Nuanced regional considerations affecting diagnostics, reimbursement pathways, supply chain resilience, and adoption timelines across global amyloidosis care geographies

Regional dynamics continue to shape access, investment, and clinical practice in ways that require tailored strategies. In the Americas, concentrated centers of excellence and a historically aggressive innovation funding environment support rapid adoption of novel therapeutics and diagnostic technologies, but divergent payer policies across public and private systems create variability in patient access and reimbursement timelines. In contrast, the Europe, Middle East & Africa region presents a heterogeneous mosaic where single-payer jurisdictions may enable more standardized adoption pathways while other markets face infrastructural constraints that delay diffusion of high-cost therapies.

Asia-Pacific markets exhibit a mix of rapid biopharmaceutical manufacturing expansion and diverse regulatory approaches; several countries within the region are building local production capabilities and regulatory frameworks that aim to both attract clinical development activity and lower dependence on external supply chains. Across regions, variations in diagnostic capacity, specialist availability, and local treatment guidelines influence how rapidly new modalities move from approval to routine care. In low-resource settings, supportive care and symptom management often remain the immediate priorities, while high-resource systems increasingly emphasize long-term disease modification and integrated care models.

Strategic entrants must therefore align commercialization, medical affairs, and supply strategies to regional nuances. This includes adapting value demonstration dossiers to local evidence requirements, investing in clinician education where diagnostic literacy remains nascent, and establishing manufacturing or sourcing partnerships to reduce tariff and logistics exposure while accelerating time to patient.

How the interplay between big pharma scale, biotech innovation, diagnostics partnerships, and manufacturing strategies is determining competitive positioning in amyloidosis

Competitive activity across the amyloidosis space reflects a mix of large pharmaceutical companies, specialized biotech innovators, contract manufacturing organizations, and diagnostics firms that together shape the innovation and access landscape. Established pharmaceutical companies with broad commercial infrastructures play a pivotal role in scaling approved therapies and negotiating complex reimbursement arrangements, while nimble biotech firms tend to drive early-stage innovation in next-generation silencers, stabilizers, and targeted biologics.

Strategic partnerships and licensing agreements have become central to accelerating clinical development and market entry. Collaborations between therapy developers and diagnostics providers are increasingly important to ensure accurate patient identification and to support companion diagnostic strategies that underpin value-based contracting. Contract manufacturing organizations and regional producers also play a critical role by offering capacity to mitigate tariff exposure and to enable localized supply chains that reduce lead times for critical therapies.

Investors and potential partners should monitor pipeline progression, regulatory milestones, and evidence-generation strategies that differentiate products in terms of clinical benefit and real-world applicability. Companies that demonstrate robust post-approval evidence collection, invest in patient support services, and proactively engage payers and clinician networks are better positioned to translate clinical promise into sustainable adoption across diverse care settings.

Actionable strategic priorities for manufacturers, payers, and providers to enhance access, ensure supply resilience, and demonstrate sustained clinical value in amyloidosis

Industry leaders should adopt a multi-pronged approach to capture clinical value and to sustain access amidst evolving policy and supply challenges. Prioritize investments in diagnostic infrastructure and clinician education to drive earlier detection and appropriate subtype assignment, thereby increasing the clinical utility of disease-modifying therapies. Concurrently, design evidence-generation plans that combine randomized data with pragmatic real-world evidence to support robust value conversations with payers and to de-risk formulary inclusion across different reimbursement environments.

Reinforce supply chain resilience through supplier diversification, selective nearshoring, and strategic inventory buffers for critical inputs. Negotiate flexible contractual terms with suppliers and logistics partners to accommodate tariff volatility and to preserve continuity of care. Align product development with route-of-administration preferences for targeted patient cohorts, recognizing that oral and subcutaneous formulations can expand home-based care opportunities while intravenous regimens often require hospital or clinic resources.

Finally, cultivate partnerships across the ecosystem-including diagnostics providers, specialty clinics, and patient advocacy groups-to build comprehensive care pathways that improve adherence, monitor outcomes, and support long-term disease management. Embrace outcome-based contracting where feasible, and invest in digital tools that enable remote monitoring and patient engagement, thereby strengthening the real-world case for therapeutic value and enabling more predictable reimbursement conversations.

Robust mixed-methods research approach combining clinical expert insights, public regulatory records, and systematic literature review to ensure evidence-driven conclusions

This analysis synthesizes primary and secondary research methods to deliver a balanced view of clinical, commercial, and operational dynamics. Primary research comprised structured interviews with key opinion leaders including hematologists, cardiologists, neurologists, specialty clinic directors, and procurement executives, combined with dialogues with industry executives to contextualize pipeline developments and commercialization strategies. Secondary research involved systematic review of peer-reviewed clinical literature, regulatory approvals and label updates, clinical trial registries, and public company disclosures, augmented by an examination of diagnostic guideline updates and payer policy announcements.

Data triangulation ensured that clinical findings align with observed commercial behaviors and supply chain realities. Qualitative insights from expert interviews were cross-validated with published trial outcomes and regulatory documentation to mitigate bias and to refine interpretations. Analytical techniques included thematic synthesis for qualitative inputs and comparative trend mapping to highlight regional and segment-level differences. The methodology prioritized transparency in assumptions and explicitly excluded speculative market sizing or forecasting to maintain focus on actionable intelligence and evidence-based recommendations.

Concluding synthesis of diagnostic advances, therapeutic diversification, and strategic actions required to translate innovation into broader patient impact

In conclusion, the amyloidosis landscape is entering a phase where diagnostic sophistication and therapeutic diversity converge to create tangible opportunities for improved patient outcomes and strategic commercial growth. Clinicians now have access to a wider array of disease-modifying agents and supportive strategies, and health systems are recalibrating care delivery to accommodate chronic management pathways. Trade policy shifts and supply chain pressures underscore the need for resilient sourcing strategies, while regional heterogeneity demands tailored market entry and evidence-generation plans.

For stakeholders across the ecosystem, the path forward involves aligning clinical innovation with pragmatic access mechanisms and operational preparedness. By investing in diagnostics, forging strategic partnerships, and collecting meaningful real-world evidence, organizations can bridge the gap between clinical potential and widespread patient benefit. The recommendations contained herein provide a roadmap for navigating the evolving therapeutic, regulatory, and commercial environment surrounding amyloidosis treatment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of RNA interference therapies reshaping hereditary transthyretin amyloidosis treatment landscape
  • 5.2. Expansion of genetic screening programs driving earlier diagnosis and intervention for amyloidosis patients
  • 5.3. Integration of advanced amyloid imaging techniques improving treatment monitoring and patient stratification
  • 5.4. Strategic alliances between biotech firms and large pharmaceutical companies accelerating novel amyloidosis drug development
  • 5.5. Reimbursement challenges and payer policy variations impacting patient access to high-cost amyloidosis treatments
  • 5.6. Emergence of monoclonal antibody therapies targeting misfolded protein aggregates in systemic amyloidosis treatment
  • 5.7. Increasing real-world evidence studies enhancing understanding of long-term efficacy and safety of amyloidosis therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Amyloidosis Treatment Market, by Treatment Type

  • 8.1. Pharmacological Treatment
    • 8.1.1. Alkylating Agents
      • 8.1.1.1. Melphalan
    • 8.1.2. Immunomodulators
      • 8.1.2.1. Lenalidomide
    • 8.1.3. Monoclonal Antibodies
      • 8.1.3.1. Daratumumab
    • 8.1.4. Proteasome Inhibitors
      • 8.1.4.1. Bortezomib
      • 8.1.4.2. Carfilzomib
      • 8.1.4.3. Ixazomib
    • 8.1.5. TTR Silencers
      • 8.1.5.1. Inotersen
      • 8.1.5.2. Patisiran
    • 8.1.6. TTR Stabilizers
      • 8.1.6.1. Acoramidis
      • 8.1.6.2. Tafamidis
  • 8.2. Stem Cell Transplantation
  • 8.3. Supportive Therapy

9. Amyloidosis Treatment Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Amyloidosis Treatment Market, by End User

  • 10.1. Home Care
  • 10.2. Hospital
  • 10.3. Specialty Clinic

11. Amyloidosis Treatment Market, by Drug Class

  • 11.1. Alkylating Agents
    • 11.1.1. Melphalan
  • 11.2. Immunomodulators
    • 11.2.1. Lenalidomide
  • 11.3. Monoclonal Antibodies
    • 11.3.1. Daratumumab
  • 11.4. Proteasome Inhibitors
    • 11.4.1. Bortezomib
    • 11.4.2. Carfilzomib
    • 11.4.3. Ixazomib
  • 11.5. TTR Silencers
    • 11.5.1. Inotersen
    • 11.5.2. Patisiran
  • 11.6. TTR Stabilizers
    • 11.6.1. Acoramidis
    • 11.6.2. Tafamidis

12. Amyloidosis Treatment Market, by Amyloidosis Type

  • 12.1. AA
  • 12.2. AL
  • 12.3. Hereditary ATTR
  • 12.4. Wild-Type ATTR

13. Amyloidosis Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Amyloidosis Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Amyloidosis Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Pfizer Inc.
    • 16.3.2. Alnylam Pharmaceuticals, Inc.
    • 16.3.3. Johnson & Johnson (Janssen Biotech, Inc.)
    • 16.3.4. Ionis Pharmaceuticals, Inc.
    • 16.3.5. BridgeBio Pharma, Inc.
    • 16.3.6. Prothena Corporation plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. AMYLOIDOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. AMYLOIDOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. AMYLOIDOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLI